CN103656749B - A kind of compound degradable antibacterial artificial dura mater and preparation method thereof - Google Patents
A kind of compound degradable antibacterial artificial dura mater and preparation method thereof Download PDFInfo
- Publication number
- CN103656749B CN103656749B CN201310659823.0A CN201310659823A CN103656749B CN 103656749 B CN103656749 B CN 103656749B CN 201310659823 A CN201310659823 A CN 201310659823A CN 103656749 B CN103656749 B CN 103656749B
- Authority
- CN
- China
- Prior art keywords
- collagen
- solution
- chitosan
- glycerophosphate
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001951 dura mater Anatomy 0.000 title claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims description 4
- 102000008186 Collagen Human genes 0.000 claims abstract description 48
- 108010035532 Collagen Proteins 0.000 claims abstract description 48
- 229920001436 collagen Polymers 0.000 claims abstract description 48
- 239000000243 solution Substances 0.000 claims abstract description 46
- 229920001661 Chitosan Polymers 0.000 claims abstract description 36
- 239000000017 hydrogel Substances 0.000 claims abstract description 20
- 239000002131 composite material Substances 0.000 claims abstract description 17
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims abstract description 16
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 claims abstract description 13
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010059993 Vancomycin Proteins 0.000 claims abstract description 12
- 229960001699 ofloxacin Drugs 0.000 claims abstract description 12
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims abstract description 12
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229960001572 vancomycin hydrochloride Drugs 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- 210000003516 pericardium Anatomy 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 210000000936 intestine Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229960002901 sodium glycerophosphate Drugs 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 210000004303 peritoneum Anatomy 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 9
- 239000011859 microparticle Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 210000002435 tendon Anatomy 0.000 claims description 7
- 229960003165 vancomycin Drugs 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 210000004379 membrane Anatomy 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 3
- 108090000284 Pepsin A Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 229940111202 pepsin Drugs 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 7
- 206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
一种复合型可降解的抗菌人工硬脑膜,包含万古霉素或盐酸氧氟沙星注射液,壳聚糖及β-甘油磷酸钠,其特点是:将脱细胞膜状生物衍生材料制成海绵状胶原生物膜支架,应用2%(w/v)壳聚糖溶液,56%(w/v)β-甘油磷酸钠溶液进行混合,根据壳聚糖与β-甘油磷酸钠溶液复合物在37℃时形成水凝胶的温度敏感性的特性,将万古霉素或盐酸氧氟沙星注射液加入壳聚糖与β-甘油磷酸钠溶液复合物的溶液浸入已经制成的海绵状胶原生物膜支架的免缝合硬脑膜,在37℃温箱内放置10min,水凝胶复合物均匀浸入海绵状胶原生物膜支架形成具有抗菌活性的可吸收的人工硬脑膜。并提供制备方法。具有制作方便,易成膜,成本低廉,便于操作等特点。A composite degradable antibacterial artificial dura mater, including vancomycin or ofloxacin hydrochloride injection, chitosan and sodium β-glycerophosphate. Collagen biofilm scaffolds were mixed with 2% (w/v) chitosan solution and 56% (w/v) β-glycerophosphate sodium solution, according to the complex of chitosan and β-glycerophosphate sodium solution at 37 To study the temperature-sensitive characteristics of hydrogel formation, add vancomycin or ofloxacin hydrochloride injection into the complex solution of chitosan and β-glycerophosphate sodium solution into the prepared spongy collagen biofilm scaffold The suture-free dura mater was placed in a 37°C incubator for 10 minutes, and the hydrogel complex was evenly immersed in the spongy collagen biofilm scaffold to form an absorbable artificial dura mater with antibacterial activity. And provide the preparation method. It has the characteristics of convenient production, easy film formation, low cost and convenient operation.
Description
技术领域 technical field
本发明属于生物材料技术领域,属于公众能够得到的生物材料,具体地说,是一种复合型可降解的抗菌人工硬脑膜及其制备方法。 The invention belongs to the technical field of biomaterials, and belongs to the biomaterials available to the public, in particular to a composite degradable antibacterial artificial dura mater and a preparation method thereof.
背景技术 Background technique
壳聚糖,英文chitosan,是p(1—4)一2一乙酰氨基一2一脱氧一D葡聚糖和2一氨基一2一脱氧一D葡聚糖的共聚物,这种聚阳离子的生物二聚体主要通过对几丁质脱乙酰基获得。由于来源广泛,无毒性、具有良好的组织相容性、生物可降解性和粘附作用,该材料在医学、生物学领域得到了深入研究和广泛应用。Chenite等(见CheniteA,ChaputC,WangD,etal.Novelinjectableneutralsolutionsofchitosanformbiodegradablegelsinsitu[J].Biomaterials,2000,21(21):2155-2161.)应用甘油磷酸钠中和壳聚糖后,得到了pH值中性且在常温下可长时间保持液态的壳聚糖/β形生成水凝胶,而且具有不致癌、不致畸形、不致突变的特性,经过灭菌已经成为一种可注射的非静脉的药物,广泛应用于组织工程学成为药物的载体和细胞支架材料。 Chitosan, English chitosan, is a copolymer of p(1-4)-2-acetylamino-2-deoxy-D dextran and 2-amino-2-deoxy-D dextran. Biodimers are mainly obtained by deacetylating chitin. Due to the wide range of sources, non-toxicity, good tissue compatibility, biodegradability and adhesion, the material has been deeply studied and widely used in the fields of medicine and biology. Chenite et al. (See CheniteA, ChaputC, WangD, et al.Novelinjectableneutralsolutionsofchitosanformbiodegradablegelsinsitu[J].Biomaterials, 2000,21(21):2155-2161.) After neutralizing chitosan with sodium glycerophosphate, neutral pH value and Chitosan/β, which can remain liquid for a long time at room temperature, forms a hydrogel, and has the characteristics of non-carcinogenic, non-teratogenic, and non-mutagenic. After sterilization, it has become an injectable non-intravenous drug and is widely used in Tissue engineering has become a drug carrier and cell scaffold material.
生物替代材料作为硬脑膜替代材料具有使用安全有效、易于操作、较柔韧、来源广泛、价格低廉等优点,良好的生物适应性。常使用牛肌腱、猪心包、牛心包、羊心包、牛腹膜、猪腹膜、肠系膜代替硬膜。但同时又有导致粘连、不易保存、不易消毒、有可能发生免疫反应等缺点。 As a dura mater substitute material, biological substitute materials have the advantages of safe and effective use, easy operation, flexibility, wide range of sources, low price, etc., and good biological adaptability. Bovine tendon, pig pericardium, bovine pericardium, sheep pericardium, bovine peritoneum, porcine peritoneum, and mesentery are often used instead of dura mater. But at the same time, it has the disadvantages of causing adhesion, not easy to preserve, not easy to disinfect, and possible immune reaction.
较为理想的人工硬脑膜应该具备以下特点:①无免疫排斥反应、无毒性反应,无致癌、致畸作用;②具有延展性,柔韧性,能够防治感染;③经过缝合或黏贴能够防止脑脊液漏,有效保护脑组织,与脑组织无粘连,无瘢痕;④在新生类脑膜样组织生成以后能够被机体完全吸收;⑤材料来源方便,容易保存;⑥价格相对适中。 An ideal artificial dura mater should have the following characteristics: ①No immune rejection, no toxic reaction, no carcinogenic and teratogenic effects; ②Extensible, flexible, and able to prevent and treat infection; ③Suture or paste can prevent cerebrospinal fluid leakage , effectively protect the brain tissue, without adhesion to the brain tissue, and without scarring; ④After the formation of new meningoid-like tissue, it can be completely absorbed by the body; ⑤The material source is convenient and easy to store; ⑥The price is relatively moderate.
现有临床应用较多的人工硬脑膜多以进口为主,如天义福(DuraMax)、冠昊(NormalGEN)、瑞之来(DuraGen)、佰仁思(Durascaffold)价格昂贵,有较多的颅内感染及排斥反应的病例。脑脊液漏的患者亦较多,均不能完全满足上述要求。 The artificial dura mater with many clinical applications is mostly imported, such as DuraMax, NormalGEN, DuraGen, and Durascaffold, which are expensive and there are many Cases of intracranial infection and rejection. There are also many patients with cerebrospinal fluid leakage, all of which cannot fully meet the above requirements.
本发明旨在研制出更加适合于临床需要的硬脑膜替代材料。 The present invention aims to develop a dura mater substitute material more suitable for clinical needs.
发明内容 Contents of the invention
本发明的目的是对现有技术进行实质性改进和创新,提供一种复合型可降解的抗菌人工硬脑膜,并提供其制备方法。其制备方法具有制作方便,易成膜,成本低廉,便于操作等特点。所制备的复合型可降解的抗菌人工硬脑为硬膜缺损部位提供有利于成纤维细胞长入和演生新硬膜组织的海绵状胶原生物膜支架,与加入万古霉素或盐酸氧氟沙星的对于温度敏感的壳聚糖/β-甘油磷酸钠复合物在37℃结合,制备出具有良好的组织相容性和可降解性,能有效地减少颅内感染和脑脊液的渗漏,同时也减少了脑组织与邻近组织之间形成瘢痕的新型复合人工硬脑膜。 The purpose of the present invention is to substantially improve and innovate the prior art, to provide a composite degradable antibacterial artificial dura mater, and to provide a preparation method thereof. The preparation method has the characteristics of convenient production, easy film formation, low cost, convenient operation and the like. The prepared composite degradable antibacterial artificial dura mater provides a spongy collagen biofilm scaffold for the dura mater defect site, which is conducive to the growth of fibroblasts and the development of new dura mater tissue. Star’s temperature-sensitive chitosan/β-sodium glycerophosphate complex is combined at 37°C to prepare a compound with good tissue compatibility and degradability, which can effectively reduce intracranial infection and cerebrospinal fluid leakage, and at the same time A new composite artificial dura mater that also reduces scarring between brain tissue and adjacent tissue.
本发明的目的是由以下技术方案来实现的:一种复合型可降解的抗菌人工硬脑膜,包含万古霉素或盐酸氧氟沙星注射液,壳聚糖及β-甘油磷酸钠,其特征是:将脱细胞膜状生物衍生材料制成海绵状胶原生物膜支架,应用2%(w/v)壳聚糖溶液8ml,56%(w/v)β-甘油磷酸钠溶液1ml进行混合,根据壳聚糖与β-甘油磷酸钠溶液复合物在37℃时形成水凝胶的温度敏感性的特性,将0.1g万古霉素或0.1g盐酸氧氟沙星注射液lml,加入壳聚糖与β-甘油磷酸钠溶液复合物的溶液浸入已经制成的海绵状胶原生物膜支架的免缝合硬脑膜,在37℃温箱内放置10min,水凝胶复合物均匀浸入海绵状胶原生物膜支架形成具有抗菌活性的可吸收的人工硬脑膜。 The object of the present invention is achieved by the following technical solutions: a composite degradable antibacterial artificial dura mater, comprising vancomycin or ofloxacin hydrochloride injection, chitosan and β-sodium glycerophosphate, its characteristics Yes: make a sponge-like collagen biofilm scaffold from decellularized membranous bio-derived materials, apply 8ml of 2% (w/v) chitosan solution and 1ml of 56% (w/v) sodium β-glycerophosphate solution, according to Chitosan and β-sodium glycerophosphate solution complexes form the temperature-sensitive characteristic of hydrogel at 37 ℃, with 0.1g vancomycin or 0.1g ofloxacin hydrochloride injection 1ml, add chitosan and The solution of β-glycerophosphate sodium solution complex is immersed in the suture-free dura mater of the prepared spongy collagen biofilm scaffold, and placed in a 37°C incubator for 10 minutes, and the hydrogel composite is evenly immersed in the spongy collagen biofilm scaffold to form Absorbable artificial dura mater with antimicrobial activity.
所述的脱细胞膜状生物衍生材料包括牛肌腱、猪心包、牛心包、羊心包、牛腹膜、猪腹膜、牛肠、猪肠和羊肠中的任意一种。 The decellularized membranous bio-derived material includes any one of bovine tendon, porcine pericardium, bovine pericardium, sheep pericardium, bovine peritoneum, porcine peritoneum, bovine intestine, pig intestine and sheep intestine.
一种复合型可降解的抗菌人工硬脑膜的制备方法,其特征是,它包括以下步骤: A preparation method of a composite degradable antibacterial artificial dura mater is characterized in that it comprises the following steps:
1)海绵状胶原生物膜支架的制备;利用胶原膜冷冻干燥后制备而成,具有多孔疏松状结构,具有良好的渗透和吸水能力,采用脱细胞膜状生物衍生材料置于75%乙醇溶液及过氧乙酸中浸泡消毒2h,用磷酸盐缓冲液反复冲洗3次;将其置于氢氧化钠溶液浸泡2h,再用磷酸盐缓冲液冲洗浸泡至PH7.4;将其放在-80℃低温液氮中冷冻24h,置于真空冻干机冷冻干燥24h,液氮冷冻粉碎机粉碎40min,9号筛网取粒径80μm以下胶原微粒,将胶原微粒与0.5%胰蛋白酶、0.2%乙二胺四乙酸即EDTA按体积比1∶5混合,4℃冰箱振荡24h,以离心半径8cm,5000r/min离心20min弃去上清液体;磷酸盐缓冲液反复清洗3次,同上法离心后弃上清液,将离心后胶原微粒与1mol/L冰醋酸按体积比1∶5混合,胶原微粒与胃蛋白酶按质量比100∶1混合,4℃冰箱连续振荡24h,去除胶原微粒中胶原分子的非螺旋区,用1mol/L氢氧化钠调节pH值至7.4,以离心半径8cm,5000r/min离心20min;弃去上清液体,三蒸水反复清洗3次,以离心半径8cm,5000r/min离心20min;弃去上清液体,沉淀物置于特制的圆柱形模具中,规格有6cm×6cm;8cm×8cm;10cm×10cm;12cm×120cm,厚度2-4毫米,以真空冻干机冷冻干燥,-80℃低温液氮中冷冻24h后,置于冷冻干燥机成型24h后取出,获得脱细胞海绵状胶原生物膜,真空包装,环氧乙烷灭菌,4℃冰箱保存备用; 1) Preparation of sponge-like collagen biofilm scaffolds; prepared by freeze-drying collagen membranes, with a porous and loose structure, good penetration and water absorption capabilities, using decellularized membrane-like bio-derived materials placed in 75% ethanol solution and over Soak it in oxyacetic acid for 2 hours, rinse it repeatedly with phosphate buffer for 3 times; soak it in sodium hydroxide solution for 2 hours, then rinse it with phosphate buffer until pH7.4; put it in -80℃ cryogenic solution Freeze in nitrogen for 24 hours, freeze-dry in a vacuum freeze dryer for 24 hours, crush in a liquid nitrogen freezer for 40 minutes, take collagen particles with a particle size of 80 μm or less through a No. 9 sieve, and mix collagen particles with 0.5% trypsin and 0.2% Mix acetic acid and EDTA at a volume ratio of 1:5, oscillate in a refrigerator at 4°C for 24 hours, centrifuge at 5000 r/min for 20 minutes with a centrifugal radius of 8 cm, and discard the supernatant; wash repeatedly with phosphate buffer for 3 times, and discard the supernatant after centrifugation as above After centrifugation, mix the collagen microparticles with 1mol/L glacial acetic acid in a volume ratio of 1:5, and mix the collagen microparticles with pepsin in a mass ratio of 100:1, and shake continuously in a refrigerator at 4°C for 24 hours to remove the non-helical regions of collagen molecules in the collagen microparticles. , adjust the pH value to 7.4 with 1mol/L sodium hydroxide, centrifuge at 5000r/min for 20min with a centrifugal radius of 8cm; discard the supernatant liquid, wash with triple distilled water repeatedly for 3 times, and centrifuge with a centrifugal radius of 8cm for 20min at 5000r/min; Discard the supernatant liquid, and place the precipitate in a special cylindrical mold with specifications of 6cm×6cm; 8cm×8cm; 10cm×10cm; 12cm×120cm, with a thickness of 2-4 mm, freeze-dried with a vacuum freeze dryer, -80 After freezing in liquid nitrogen at low temperature for 24 hours, place it in a freeze dryer for 24 hours and take it out to obtain acellular sponge-like collagen biofilm, vacuum pack it, sterilize it with ethylene oxide, and store it in a refrigerator at 4°C for later use;
2)壳聚糖/β-甘油磷酸钠复合物的制备:取36%浓盐酸0.43ml,加三蒸水至总液量为50ml,取0.43ml盐酸加入三蒸水的50ml容量瓶中,加三蒸水定容为50毫升,配制成0.1M的稀盐酸,壳聚糖规格是:粘度150mPa.s,分子量8.13万道尔顿,脱乙酞度91%,2g壳聚糖溶解于0.1M的稀盐酸,23℃室温下以磁力搅拌器充分搅拌30分钟,转速450r/min,混匀制成总量100ml溶液,制备成2%(w/v)壳聚糖溶液,121℃高压消毒30min,4℃冰箱保存备用,56%(w/v)β-甘油磷酸钠溶液配制56gβ-甘油磷酸钠,加三蒸水完全溶解,定容至100ml,过滤除菌,121℃高压消毒30min,4℃冰箱保存备用,2%(w/v)壳聚糖与56%(w/v)β-甘油磷酸钠以8:1的比例配制,pH值为7.25,37℃水浴中成为水凝胶时间为6分钟; 2) Preparation of chitosan/β-sodium glycerophosphate complex: take 0.43ml of 36% concentrated hydrochloric acid, add three-distilled water to a total liquid volume of 50ml, take 0.43ml of hydrochloric acid and add three-distilled water to a 50ml volumetric flask, add The volume of three distilled water is 50 ml, and it is prepared into 0.1M dilute hydrochloric acid. The specifications of chitosan are: viscosity 150mPa. dilute hydrochloric acid, fully stirred with a magnetic stirrer at room temperature at 23°C for 30 minutes, at a speed of 450r/min, and mixed to make a total of 100ml solution, prepared as a 2% (w/v) chitosan solution, and sterilized under high pressure at 121°C for 30min , Store in refrigerator at 4°C for later use, prepare 56g of β-glycerophosphate sodium solution with 56% (w/v) sodium β-glycerophosphate solution, add triple distilled water to dissolve completely, set the volume to 100ml, filter and sterilize, autoclave at 121°C for 30 minutes, 4 Store in the refrigerator at ℃ for later use, prepare 2% (w/v) chitosan and 56% (w/v) sodium β-glycerophosphate at a ratio of 8:1, the pH value is 7.25, and the time to become a hydrogel in a 37°C water bath is 6 minutes;
3)取2%(w/v)壳聚糖溶液8ml:56%(w/v)β-甘油磷酸钠溶液1ml:0.1g万古霉素或0.1g盐酸氧氟沙星注射液lml,三者在4℃均匀混合后,以脱细胞海绵状胶原生物膜浸入上述混合溶液,在37℃温箱内放置10分钟,混合溶液形成水凝胶与胶原生物膜融为一体。 3) Take 8ml of 2% (w/v) chitosan solution: 1ml of 56% (w/v) sodium β-glycerophosphate solution: 0.1g vancomycin or 0.1g ofloxacin hydrochloride injection lml, the three After uniform mixing at 4°C, the decellularized sponge-like collagen biofilm was immersed in the above mixed solution, and placed in a 37°C incubator for 10 minutes, and the mixed solution formed a hydrogel and integrated with the collagen biofilm.
本发明的一种复合型可降解的抗菌人工硬脑膜,由采用水凝胶复合物均匀浸入海绵状胶原生物膜形成的,因为有水凝胶的存在术中可不需要缝合,与组织有良好的相容性,经过实验证明无脑脊液漏发生;水凝胶中的万古霉素或盐酸氧氟沙星在水凝胶逐渐降解中缓慢释放,达到防治颅内感染的目的;海绵状胶原膜降解速度与人体自身硬膜生长速度相似,具有良好的可吸收性和组织学相容性;材料来源广泛,价格低廉,使用安全,寿命长。 A composite degradable antibacterial artificial dura mater of the present invention is formed by evenly soaking the spongy collagen biofilm with a hydrogel compound, because there is no need for suturing during the operation due to the presence of the hydrogel, and it has a good connection with the tissue Compatibility, experiments have proved that no cerebrospinal fluid leakage occurs; the vancomycin or ofloxacin hydrogel in the hydrogel is slowly released during the gradual degradation of the hydrogel, achieving the purpose of preventing and treating intracranial infection; the degradation speed of the spongy collagen membrane Similar to the growth rate of the human body's own dura mater, it has good absorbability and histological compatibility; the material has a wide range of sources, low price, safe use, and long life.
本发明的复合型可降解的抗菌人工硬脑膜的制备方法科学、合理,制备流程容易操控,成膜质量好,生物学特性好。 The preparation method of the composite degradable antibacterial artificial dura mater of the present invention is scientific and reasonable, the preparation process is easy to control, the film forming quality is good, and the biological characteristics are good.
具体实施方式 detailed description
下面结合实施例对本发明作进一步说明。 The present invention will be further described below in conjunction with embodiment.
一种复合型可降解的抗菌人工硬脑膜,包含万古霉素或盐酸氧氟沙星注射液,壳聚糖及β-甘油磷酸钠,其特征是:将脱细胞膜状生物衍生材料制成海绵状胶原生物膜支架,应用2%(w/v)壳聚糖溶液8ml,56%(w/v)β-甘油磷酸钠溶液1ml进行混合,根据壳聚糖与β-甘油磷酸钠溶液复合物在37℃时形成水凝胶的温度敏感性的特性,将0.1g万古霉素或0.1g盐酸氧氟沙星注射液lml加入壳聚糖与β-甘油磷酸钠溶液复合物的溶液浸入已经制成的海绵状胶原生物膜支架的免缝合硬脑膜,在37℃温箱内放置10min,水凝胶复合物均匀浸入海绵状胶原生物膜支架形成具有抗菌活性的可吸收的人工硬脑膜。 A composite degradable antibacterial artificial dura mater, including vancomycin or ofloxacin hydrochloride injection, chitosan and sodium β-glycerophosphate, characterized in that the decellularized membrane-like biological derivative material is made into a sponge Collagen biofilm scaffold, apply 2% (w/v) chitosan solution 8ml, 56% (w/v) β-sodium glycerophosphate solution 1ml mixes, according to chitosan and β-sodium glycerophosphate solution complex in The temperature sensitivity of hydrogel formation at 37°C, 0.1g vancomycin or 0.1g ofloxacin hydrochloride injection 1ml is added to the solution of chitosan and β-sodium glycerophosphate solution and immersed in the prepared The suture-free dura mater of the spongy collagen biofilm scaffold was placed in a 37°C incubator for 10 minutes, and the hydrogel complex was evenly immersed in the spongy collagen biofilm scaffold to form an absorbable artificial dura mater with antibacterial activity.
所述的脱细胞膜状生物衍生材料包括牛肌腱、猪心包、牛心包、羊心包、牛腹膜、猪腹膜、牛肠、猪肠和羊肠中的任意一种。 The decellularized membranous bio-derived material includes any one of bovine tendon, porcine pericardium, bovine pericardium, sheep pericardium, bovine peritoneum, porcine peritoneum, bovine intestine, pig intestine and sheep intestine.
本发明通过9个实施例的具体实施,分别采用牛肌腱、猪心包、牛心包、羊心包、牛腹膜、猪腹膜、牛肠、猪肠和羊肠对复合型可降解的抗菌人工硬脑膜进行制备,均获得成功。 Through the specific implementation of 9 embodiments, the present invention uses bovine tendon, porcine pericardium, bovine pericardium, sheep pericardium, bovine peritoneum, porcine peritoneum, bovine intestine, pig intestine and sheep intestine to treat the composite degradable antibacterial artificial dura mater. Preparations were all successful.
实施例1:现以作为脱细胞膜状生物衍生材料之一的牛肌腱为例说明其具体复合型可降解的抗菌人工硬脑膜进行制备方法,对于所述其它脱细胞膜状生物衍生材料同实施例1:包括以下步骤: Example 1: Taking bovine tendon as one of the decellularized membranous biologically derived materials as an example to illustrate its specific composite degradable antibacterial artificial dura mater preparation method, the other decellularized membranous biologically derived materials are the same as in Example 1 : Include the following steps:
1)海绵状胶原生物膜支架的制备;利用胶原膜冷冻干燥后制备而成,具有多孔疏松状结构,具有良好的渗透和吸水能力,采用脱细胞膜状生物衍生材料之一的牛肌腱置于75%乙醇溶液及过氧乙酸中浸泡消毒2h,用磷酸盐缓冲液反复冲洗3次;将其置于氢氧化钠溶液浸泡2h,再用磷酸盐缓冲液冲洗浸泡至PH7.4;将其放在-80℃低温液氮中冷冻24h,置于真空冻干机冷冻干燥24h,液氮冷冻粉碎机粉碎40min,9号筛网取粒径80μm以下胶原微粒,将胶原微粒与0.5%胰蛋白酶、0.2%乙二胺四乙酸即EDTA按体积比1∶5混合,4℃冰箱振荡24h,以离心半径8cm,5000r/min离心20min弃去上清液体;磷酸盐缓冲液反复清洗3次,同上法离心后弃上清液,将离心后胶原微粒与1mol/L冰醋酸按体积比1∶5混合,胶原微粒与胃蛋白酶按质量比100∶1混合,4℃冰箱连续振24h,去除胶原微粒中胶原分子的非螺旋区,用1mol/L氢氧化钠调节pH值至7.4,以离心半径8cm,5000r/min离心20min;弃去上清液体,三蒸水反复清洗3次,以离心半径8cm,5000r/min离心20min;弃去上清液体,沉淀物置于特制的圆柱形模具中,规格有6cm×6cm;8cm×8cm;10cm×10cm;12cm×120cm,厚度2-4毫米,以真空冻干机冷冻干燥,-80℃低温液氮中冷冻24h后,置于冷冻干燥机成型24h后取出,获得脱细胞海绵状胶原生物膜,真空包装,环氧乙烷灭菌,4℃冰箱保存备用; 1) Preparation of sponge-like collagen biofilm scaffolds; prepared by freeze-drying collagen membranes, with a porous and loose structure, and good penetration and water absorption capabilities. Bovine tendon, one of the decellularized membrane-like bio-derived materials, was placed at 75 % ethanol solution and peracetic acid for 2 hours, rinsed repeatedly with phosphate buffer for 3 times; soaked in sodium hydroxide solution for 2 hours, then rinsed with phosphate buffer until pH7.4; Freeze in low-temperature liquid nitrogen at -80°C for 24 hours, freeze-dry in a vacuum freeze dryer for 24 hours, pulverize with a liquid nitrogen freezer pulverizer for 40 minutes, take collagen particles with a particle size of 80 μm or less through a No. 9 sieve, mix collagen particles with 0.5% trypsin, 0.2 %ethylenediaminetetraacetic acid (EDTA) was mixed at a volume ratio of 1:5, oscillated in a refrigerator at 4°C for 24 hours, centrifuged at 5000r/min for 20min with a centrifugal radius of 8cm, discarded the supernatant liquid; washed repeatedly with phosphate buffer for 3 times, and centrifuged as above Discard the supernatant, mix the centrifuged collagen microparticles with 1mol/L glacial acetic acid at a volume ratio of 1:5, and mix the collagen microparticles with pepsin at a mass ratio of 100:1, and shake continuously at 4°C for 24 hours to remove the collagen in the collagen microparticles. For the non-helical region of the molecule, adjust the pH value to 7.4 with 1mol/L sodium hydroxide, centrifuge at 5000r/min for 20min with a centrifugal radius of 8cm; /min centrifuge for 20min; discard the supernatant, and place the sediment in a special cylindrical mold with specifications of 6cm×6cm; 8cm×8cm; 10cm×10cm; 12cm×120cm, with a thickness of 2-4mm. Freeze-dried, frozen in -80°C low-temperature liquid nitrogen for 24 hours, placed in a freeze dryer for 24 hours and taken out to obtain acellular sponge-like collagen biofilm, vacuum-packed, ethylene oxide sterilized, and stored in a 4°C refrigerator for later use;
2)壳聚糖/β-甘油磷酸钠复合物的制备:取36%浓盐酸0.43ml,加三蒸水至总液量为50ml,取0.43ml盐酸加入三蒸水的50ml容量瓶中,加三蒸水定容为50毫升,配制成0.1M的稀盐酸,壳聚糖规格是:粘度150mPa.s,分子量8.13万道尔顿,脱乙酞度91%,2g壳聚糖溶解于0.1M的稀盐酸,23℃室温下以磁力搅拌器充分搅拌30分钟,转速450r/min,混匀制成总量100ml溶液,制备成2%(w/v)壳聚糖溶液,121℃高压消毒30min,4℃冰箱保存备用,56%(w/v)β-甘油磷酸钠溶液配制56gβ-甘油磷酸钠,加三蒸水完全溶解,定容至100ml,过滤除菌,121℃高压消毒30min,4℃冰箱保存备用,2%(w/v)壳聚糖与56%(w/v)β-甘油磷酸钠以8:1的比例配制,pH值为7.25,37℃水浴中成为水凝胶时间为6分钟; 2) Preparation of chitosan/β-sodium glycerophosphate complex: take 0.43ml of 36% concentrated hydrochloric acid, add three-distilled water to a total liquid volume of 50ml, take 0.43ml of hydrochloric acid and add three-distilled water to a 50ml volumetric flask, add The volume of three distilled water is 50 ml, and it is prepared into 0.1M dilute hydrochloric acid. The specifications of chitosan are: viscosity 150mPa. dilute hydrochloric acid, fully stirred with a magnetic stirrer at room temperature at 23°C for 30 minutes, at a speed of 450r/min, and mixed to make a total of 100ml solution, prepared as a 2% (w/v) chitosan solution, and sterilized under high pressure at 121°C for 30min , Store in refrigerator at 4°C for later use, prepare 56g of β-glycerophosphate sodium solution with 56% (w/v) sodium β-glycerophosphate solution, add triple distilled water to dissolve completely, set the volume to 100ml, filter and sterilize, autoclave at 121°C for 30 minutes, 4 Store in the refrigerator at ℃ for later use, prepare 2% (w/v) chitosan and 56% (w/v) sodium β-glycerophosphate at a ratio of 8:1, the pH value is 7.25, and the time to become a hydrogel in a 37°C water bath is 6 minutes;
3)取2%(w/v)壳聚糖溶液8ml:56%(w/v)β-甘油磷酸钠溶液1ml:0.1g万古霉素或0.1g盐酸氧氟沙星注射液lml,三者在4℃均匀混合后,以脱细胞海绵状胶原生物膜浸入上述混合溶液,在37℃温箱内放置10分钟,混合溶液形成水凝胶与胶原生物膜融为一体。 3) Take 8ml of 2% (w/v) chitosan solution: 1ml of 56% (w/v) sodium β-glycerophosphate solution: 0.1g vancomycin or 0.1g ofloxacin hydrochloride injection lml, the three After uniform mixing at 4°C, the decellularized sponge-like collagen biofilm was immersed in the above mixed solution, and placed in a 37°C incubator for 10 minutes, and the mixed solution formed a hydrogel and integrated with the collagen biofilm.
用本发明一种复合型可降解的抗菌人工硬脑膜制备方法制成的复合型可降解的抗菌人工硬脑膜,经过30例群体1-10个月的使用,效果良好,实现了本发明目的和达到了所述的效果。 The composite degradable antibacterial artificial dura mater made by a kind of composite degradable antibacterial artificial dura mater preparation method of the present invention, after 1-10 month's use of 30 cases groups, the effect is good, has realized the purpose of the present invention and achieved the stated effect.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310659823.0A CN103656749B (en) | 2013-12-10 | 2013-12-10 | A kind of compound degradable antibacterial artificial dura mater and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310659823.0A CN103656749B (en) | 2013-12-10 | 2013-12-10 | A kind of compound degradable antibacterial artificial dura mater and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103656749A CN103656749A (en) | 2014-03-26 |
CN103656749B true CN103656749B (en) | 2016-01-20 |
Family
ID=50296302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310659823.0A Expired - Fee Related CN103656749B (en) | 2013-12-10 | 2013-12-10 | A kind of compound degradable antibacterial artificial dura mater and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103656749B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189955B (en) * | 2014-08-08 | 2016-06-15 | 江西瑞济生物工程技术股份有限公司 | The duramater reparation support of degradable people's amnion and ox back tendon compound and preparation method |
CN105903077B (en) * | 2016-04-14 | 2019-05-21 | 山东景源生物科技有限公司 | For promoting the preparation method, gelling performance measuring method and application of the bio-matrix gel rubber material of regenerating bone or cartilage reparation |
CN106474563B (en) * | 2016-12-02 | 2019-04-16 | 上海其胜生物制剂有限公司 | A kind of method of reversal temperature sensitive technology preparation artificial dura mater |
CN106725743A (en) * | 2017-01-11 | 2017-05-31 | 首都医科大学附属北京天坛医院 | A kind of huge and very significant meningioma overall cutting method |
CN109260472A (en) * | 2018-09-28 | 2019-01-25 | 上海理工大学 | Multi-functional temperature sensitive aquagel of one kind and its preparation method and application |
CN112089890A (en) * | 2020-08-28 | 2020-12-18 | 广东乾晖生物科技有限公司 | Acellular matrix hydrogel and preparation method and application thereof |
CN113769168A (en) * | 2021-08-16 | 2021-12-10 | 江苏优创生物医学科技有限公司 | Acellular matrix particle product for soft tissue filling repair and preparation method thereof |
CN114887119A (en) * | 2022-05-09 | 2022-08-12 | 浙江大学医学院附属第一医院 | High-molecular artificial dura mater with anti-infection capacity and preparation method thereof |
CN117547653A (en) * | 2023-12-28 | 2024-02-13 | 深圳市迈捷生命科学有限公司 | A kind of hyaluronic acid modified decellularized scaffold and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1317297A (en) * | 2000-04-11 | 2001-10-17 | 张保军 | Absorbable artificial dura meter of brain and its preparing process |
CN101361989A (en) * | 2008-09-03 | 2009-02-11 | 陕西瑞盛生物科技有限公司 | Double membrane tissue patching material and preparation method thereof |
CN102399378A (en) * | 2010-09-07 | 2012-04-04 | 中国人民解放军总医院 | A kind of temperature-sensitive chitosan hydrogel and preparation method thereof |
-
2013
- 2013-12-10 CN CN201310659823.0A patent/CN103656749B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1317297A (en) * | 2000-04-11 | 2001-10-17 | 张保军 | Absorbable artificial dura meter of brain and its preparing process |
CN101361989A (en) * | 2008-09-03 | 2009-02-11 | 陕西瑞盛生物科技有限公司 | Double membrane tissue patching material and preparation method thereof |
CN102399378A (en) * | 2010-09-07 | 2012-04-04 | 中国人民解放军总医院 | A kind of temperature-sensitive chitosan hydrogel and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103656749A (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103656749B (en) | A kind of compound degradable antibacterial artificial dura mater and preparation method thereof | |
Tang et al. | Highly absorbent bio-sponge based on carboxymethyl chitosan/poly-γ-glutamic acid/platelet-rich plasma for hemostasis and wound healing | |
Notario-Pérez et al. | Applications of chitosan in surgical and post-surgical materials | |
Giraldo-Gomez et al. | Fast cyclical-decellularized trachea as a natural 3D scaffold for organ engineering | |
Geng et al. | Microenvironment‐Responsive Hydrogels with Detachable Skin Adhesion and Mild‐Temperature Photothermal Property for Chronic Wound Healing | |
CN101773687B (en) | Preparation method of composite soft-tissue patch | |
Cheng et al. | First‐aid hydrogel wound dressing with reliable hemostatic and antibacterial capability for traumatic injuries | |
CN104117096A (en) | Novel composite biological dura mater | |
CN108187119B (en) | Cellulose-based antibacterial hemostatic material and preparation method thereof | |
Wei et al. | By endowing polyglutamic acid/polylysine composite hydrogel with super intrinsic characteristics to enhance its wound repair potential | |
Li et al. | Biomimetic multifunctional hybrid sponge via enzymatic cross-linking to accelerate infected burn wound healing | |
Huang et al. | A multifunctional 3D dressing unit based on the core–shell hydrogel microfiber for diabetic foot wound healing | |
RU2699362C2 (en) | Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for treating wounds | |
CN113234125A (en) | Self-assembly polypeptide, polypeptide hydrogel, preparation method and application thereof | |
CN107469137B (en) | Injectable hemostatic hydrogel material and preparation method and application thereof | |
CN112876700A (en) | Double-network hydrogel wound dressing and preparation method thereof | |
CN113301928B (en) | Biological scaffolds and methods for making same | |
CN101401975A (en) | Tissue engineering bone carrying sustained-release antimicrobial peptide and preparation method thereof | |
CN104474573A (en) | Biological mask and preparation method thereof | |
Chen et al. | Self-assembled near-infrared-photothermal antibacterial Hericium erinaceus β-glucan/tannic acid/Fe (III) hydrogel for accelerating infected wound healing | |
CN101856515A (en) | Method for preparing artificial bone from chitosan and shell powder | |
Yin et al. | Multifunctional all-in-one adhesive hydrogel for the treatment of perianal infectious wounds | |
CN104758983B (en) | Preparation method and application of bFGF-loaded fish collagen-based composite material | |
TWI526488B (en) | Chemical crosslinking composition, bio-medical material containing the same and use of the same | |
CN114917400B (en) | Polylysine antibacterial tissue adhesive and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20211210 |